BRKR vs. PKI, AVTR, TXG, A, MTD, WAT, ILMN, TECH, CRL, and BIO
Should you be buying Bruker stock or one of its competitors? The main competitors of Bruker include Revvity (PKI), Avantor (AVTR), 10x Genomics (TXG), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO).
Bruker (NASDAQ:BRKR) and Revvity (NYSE:PKI) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
79.5% of Bruker shares are held by institutional investors. Comparatively, 85.2% of Revvity shares are held by institutional investors. 28.3% of Bruker shares are held by insiders. Comparatively, 0.5% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Bruker received 167 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 64.82% of users gave Bruker an outperform vote while only 60.24% of users gave Revvity an outperform vote.
Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays an annual dividend of $0.28 per share. Bruker pays out 7.3% of its earnings in the form of a dividend. Revvity pays out 3.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Bruker has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Revvity has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Revvity has a net margin of 28.94% compared to Bruker's net margin of 13.38%. Bruker's return on equity of 27.31% beat Revvity's return on equity.
In the previous week, Bruker had 11 more articles in the media than Revvity. MarketBeat recorded 11 mentions for Bruker and 0 mentions for Revvity. Revvity's average media sentiment score of 0.73 beat Bruker's score of 0.56 indicating that Revvity is being referred to more favorably in the news media.
Bruker currently has a consensus target price of $85.00, indicating a potential upside of 29.69%. Revvity has a consensus target price of $54.00, indicating a potential upside of ∞. Given Revvity's stronger consensus rating and higher possible upside, analysts plainly believe Revvity is more favorable than Bruker.
Revvity has higher revenue and earnings than Bruker. Revvity is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
Summary
Bruker beats Revvity on 10 of the 19 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
